| 发明名称 |
Hepatitis C Virus Inhibitors |
| 摘要 |
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein. |
| 申请公布号 |
US2015297568(A1) |
申请公布日期 |
2015.10.22 |
| 申请号 |
US201514753564 |
申请日期 |
2015.06.29 |
| 申请人 |
BRISTOL-MYERS SQUIBB COMPANY |
发明人 |
Hewawasam Piyasena;Lopez Omar D.;Tu Yong;Wang Alan Xiangdong;Xu Ningning;Kadow John F.;Meanwell Nicholas A.;Gupta Samayamunthula Venkata Satya Arun Kumar;Kumar Indasi J. Gopi;Ponugupati Suresh Kumar;Belema Makonen |
| 分类号 |
A61K31/4178;A61K38/21;A61K31/7056;A61K31/4184;A61K31/4188;A61K31/5377;A61K31/519;A61K31/695;A61K31/4725;A61K31/437;A61K31/454;A61K31/4545;A61K31/402;A61K31/5365 |
主分类号 |
A61K31/4178 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A combination comprising an NS5A-targeting compound and an NS5A synergist, which, when administered, provides synergistic anti-HCV activity against variants that contain mutation(s) conferring resistance to the NS5A-targeting compound alone, wherein the NS5A synergist is selected from:RRRRRRRRRRRRRRRRRRRRRRRRR1R2H;RRRRRRRRRRor a pharmaceutically acceptable salt thereof. |
| 地址 |
Princeton NJ US |
